What is Bicara Therapeutics's exercised (in shares)?

Bicara Therapeutics (BCAX) reported exercised (in shares) of $4.34 in Q1 2026.

What does exercised (in shares) mean?

The weighted average exercise price at which employees and directors exercised their stock options during the period. This provides insight into the historical price levels at which equity incentives were realized by participants.

Bicara Therapeutics BCAX Exercised (in shares)

Exercised (in shares) at other companies

CorvelCRVL

$35.52-17.0%

John Wiley & Sons, Inc.WLYB

$32.68-8.4%

WhirlpoolWHR

$79.56+56.1%

HNIHNI

$38.11-14.0%

CalixCALX

$31.62+0.5%

TRV

Trevi Therapeutics, Inc.TRVI

$2.11-14.6%

Other financials

Income statement

See full

Operating income-$60.2M-44.2%

Net income-$56.2M-52.6%

EPS (diluted)-$0.93-36.8%

Balance sheet

See full

Cash & equivalents$323.5M-30.0%

Total debt$1.4M+144%

Total equity$514.0M+12.0%

Total assets$553.6M+15.8%

Cash flow

See full

Operating cash flow-$37.5M-33.5%

CapEx$60.0K—

Free cash flow-$37.6M-33.7%

Valuation

See full

Market cap$1.64B+81.4%

Enterprise value$1.32B+288%

Returns & leverage

See full

Return on equity-32.3%—

Debt / equity0×0.0×

Current ratio13.9×-10.8×

Where this comes from

Reported directly by Bicara Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice.

The official record: Bicara Therapeutics’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about Bicara Therapeutics's exercised (in shares).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Bicara Therapeutics's exercised (in shares)?: Bicara Therapeutics (BCAX) reported exercised (in shares) of $4.34 in Q1 2026.
What does exercised (in shares) mean?: The weighted average exercise price at which employees and directors exercised their stock options during the period. This provides insight into the historical price levels at which equity incentives were realized by participants.